ECSP088287A - Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma - Google Patents

Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma

Info

Publication number
ECSP088287A
ECSP088287A EC2008008287A ECSP088287A ECSP088287A EC SP088287 A ECSP088287 A EC SP088287A EC 2008008287 A EC2008008287 A EC 2008008287A EC SP088287 A ECSP088287 A EC SP088287A EC SP088287 A ECSP088287 A EC SP088287A
Authority
EC
Ecuador
Prior art keywords
copd
asthma
compounds
treatment
combination
Prior art date
Application number
EC2008008287A
Other languages
English (en)
Inventor
Tomas Eriksson
Johan Hansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37771856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088287A publication Critical patent/ECSP088287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee composiciones farmacéuticas que comprenden un glucocorticosteroide y un compuesto de la fórmula: en donde m, R1, R2, R3 y R4 tienen las definiciones indicadas en la descripción, y su uso en terapia.
EC2008008287A 2005-08-26 2008-03-17 Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma ECSP088287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501896 2005-08-26
SE0601220 2006-06-01

Publications (1)

Publication Number Publication Date
ECSP088287A true ECSP088287A (es) 2008-04-28

Family

ID=37771856

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008287A ECSP088287A (es) 2005-08-26 2008-03-17 Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma

Country Status (18)

Country Link
US (1) US20090215732A1 (es)
EP (1) EP1922074B1 (es)
JP (1) JP2009506028A (es)
KR (1) KR20080038361A (es)
AR (1) AR055614A1 (es)
AT (1) ATE457731T1 (es)
AU (2) AU2006282121B2 (es)
BR (1) BRPI0615110A2 (es)
CA (1) CA2620847A1 (es)
DE (1) DE602006012332D1 (es)
EC (1) ECSP088287A (es)
IL (2) IL189195A0 (es)
MX (1) MX2008002321A (es)
NO (1) NO20081480L (es)
RU (1) RU2414222C2 (es)
TW (1) TW200744612A (es)
UY (1) UY29760A1 (es)
WO (1) WO2007024182A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
EP2125728A4 (en) * 2007-02-23 2011-06-22 Astrazeneca Ab NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2008103126A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
WO2009142588A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) a chemokine receptor 1 (ccr1) antagonist and (b) glucocorticoid receptor modulator
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
RU2386438C1 (ru) * 2008-12-04 2010-04-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ комплексного лечения хронической обструктивной болезни легких в стадии ремиссии
TWI597072B (zh) 2011-10-11 2017-09-01 吉斯藥品公司 包覆脂肪酸的β－致效劑之結晶微粒
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
JP2023536815A (ja) * 2020-07-28 2023-08-30 スサヴィオン バイオサイエンシーズ インコーポレイテッド 好中球駆動性炎症性病変の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) * 1972-05-19 1975-08-18 Bofors Ab
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
JP2004516238A (ja) * 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのｎ−ウレイドアルキル−ピペリジン
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
KR100831534B1 (ko) * 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
EP1646392A4 (en) * 2003-07-15 2007-02-28 Merck & Co Inc 7- and 8-membered heterocyclic cyclopentyl-benzylamide modulators of the chemokine-receptor activity

Also Published As

Publication number Publication date
RU2414222C2 (ru) 2011-03-20
UY29760A1 (es) 2007-03-30
RU2008108175A (ru) 2009-10-10
IL189195A0 (en) 2008-08-07
JP2009506028A (ja) 2009-02-12
KR20080038361A (ko) 2008-05-06
NO20081480L (no) 2008-05-16
AU2006282121A1 (en) 2007-03-01
EP1922074B1 (en) 2010-02-17
EP1922074A1 (en) 2008-05-21
DE602006012332D1 (de) 2010-04-01
MX2008002321A (es) 2008-03-14
AU2006282121B2 (en) 2009-12-24
AU2009202925A1 (en) 2009-08-06
WO2007024182A1 (en) 2007-03-01
HK1116095A1 (en) 2008-12-19
ATE457731T1 (de) 2010-03-15
AU2009202925B2 (en) 2011-04-28
US20090215732A1 (en) 2009-08-27
AR055614A1 (es) 2007-08-29
CA2620847A1 (en) 2007-03-01
BRPI0615110A2 (pt) 2011-05-03
IL199022A0 (en) 2010-02-17
TW200744612A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
UY31686A1 (es) Nueva dosificacion y formulacion
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
CY1117571T1 (el) Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων
UY31687A1 (es) Nueva dosificacion y formulacion
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
UY31526A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
PA8774101A1 (es) Compuesto de pirmidina
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
NO20073900L (no) Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
AR047386A1 (es) Uso de pteridinas sustituidas para el tratamiento de enfermedades de las vias respiratorias
DK2380584T3 (da) Immunstimulerende fremgangsmåde
UY28596A1 (es) Nuevo anhidrato cristalino con accion anticolinergica
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados